The Electrolytic Recovery of Copper and Zinc from Scrap Brass with Special Reference to Lead-Bearing Brass.

Several methods have been investigated, with some success, for treating scrap brass to recover copper and zinc, either as pure metals or as salts of the metals. One of the more promising of these methods is electrolysis in sulfate solution for the recovery of pure copper and zinc.

Screening for carriage of methicillin-resistant Staphylococcus aureus shortly after exposure may lead to false-negative results

We evaluated a double screening strategy for carriage of methicillin-resistant Staphylococcus aureus (MRSA) in patients exposed to a newly detected MRSA carrier. If the first screening of the exposed patient yielded negative results, screening was repeated 4 days later. This strategy detected 12 (28%) of the 43 new MRSA carriers identified during the study period. The results suggest that there is an incubation period before MRSA carriage is detectable.

The Electroformation of Lithium-Lead Alloys from Molten Electrolytes

An attempt was made to make lead-lithium alloys by electrodeposition of lithium using a molten bath and a molten lead cathode.The variables taken into consideration were: composition of the melt, temperature of the melt, and current density. The purpose of changing these factors was to determine what effect each had on the current efficiency.

Some Effects of the Addition of Tellurium to Lead Alloys

From the standpoint of its practical useful­ness, the most important characteristics of metallic lead are its cheapness, resistance to corrosion, plas­ticity, high specific gravity, low melting point, and its ability to form alloys in which some properties are modified by the addition of other elements, while other properties remain the same.

Flotation Concentration of a Montana Lead-Zinc-Silver-Ore

The Mike Horse mine, in the Huddelston mining district, is fifty-two miles northwest of Helena, Montana. The mine was discovered in 1898 by Joseph Heitmiller. There was only minor production from the date of discovery until 1915; the main drawback being lack of good road.

Benefication of an Oxidized Lead Ore from the Franklin Mine Lewis and Clark County

This thesis is concerned with the beneficiation of an oxidized lead ore. Emphasis was placed upon concentration by flotation rather than by gravity methods, although some investigation was made with the Wilfley shaking table. The concentration of lead minerals received most consideration in the problem, but wherever possible attempts were made to increase the silver and gold concentration along with the lead.

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)

BACKGROUND: Unlike most antihyperglycaemic drugs, glucagon-like peptide-1 (GLP-1) receptor agonists have a glucose-dependent action and promote weight loss. We compared the efficacy and safety of liraglutide, a human GLP-1 analogue, with exenatide, an exendin-based GLP-1 receptor agonist. METHODS: Adults with inadequately controlled type 2 diabetes on maximally tolerated doses of metformin, sulphonylurea, or both, were stratified by previous oral antidiabetic therapy and randomly assigned to receive additional liraglutide 1.8 mg once a day (n=233) or exenatide 10 microg twice a day (n=231) in a 26-week open-label, parallel-group, multinational (15 countries) study. The primary outcome was change in glycosylated haemoglobin (HbA(1c)). Efficacy analyses were by intention to treat. The trial is registered with ClinicalTrials.gov, number NCT00518882. FINDINGS: Mean baseline HbA(1c) for the study population was 8.2%. Liraglutide reduced mean HbA(1c) significantly more than did exenatide (-1.12% [SE 0.08] vs -0.79% [0.08]; estimated treatment difference -0.33; 95% CI -0.47 to -0.18; p<0.0001) and more patients achieved a HbA(1c) value of less than 7% (54%vs 43%, respectively; odds ratio 2.02; 95% CI 1.31 to 3.11; p=0.0015). Liraglutide reduced mean fasting plasma glucose more than did exenatide (-1.61 mmol/L [SE 0.20] vs -0.60 mmol/L [0.20]; estimated treatment difference -1.01 mmol/L; 95% CI -1.37 to -0.65; p<0.0001) but postprandial glucose control was less effective after breakfast and dinner. Both drugs promoted similar weight losses (liraglutide -3.24 kg vs exenatide -2.87 kg). Both drugs were well tolerated, but nausea was less persistent (estimated treatment rate ratio 0.448, p<0.0001) and minor hypoglycaemia less frequent with liraglutide than with exenatide (1.93 vs 2.60 events per patient per year; rate ratio 0.55; 95% CI 0.34 to 0.88; p=0.0131; 25.5%vs 33.6% had minor hypoglycaemia). Two patients taking both exenatide and a sulphonylurea had a major hypoglycaemic episode. INTERPRETATION: Liraglutide once a day provided significantly greater improvements in glycaemic control than did exenatide twice a day, and was generally better tolerated. The results suggest that liraglutide might be a treatment option for type 2 diabetes, especially when weight loss and risk of hypoglycaemia are major considerations.